The Pharmacogenomics of Hydroxyurea in Sickle Cell Disease
| Short Name | PharmHU
|
|---|---|
| Institution(s) |
University of Texas Health at Houston
|
| Type of Omics | WGS
RNASeq
|
| Approx. Sample Size | 1454 |
| Disease/Phenotype |
sickle cell disease
|
| Starting Phase | Phase 2
|
| dbGaP ID | |
| TOPMed Accession # |
Please see this TOPMed Project's Parent Studies.
|
| Omics Center(s) Phase 2 |
Baylor College of Medicine Human Genome Sequencing Center
|
| Omics Center(s) Phase 6 |
Northwest Genomics Center
|
| Phases Involved |
2
6
|
| Populations |
Pediatric Patients with Sickle Cell Anemia and History of Hydroxyurea Use
|
| PI | |
| Co-PI | |
| NIH Program Officer | |
| Phenotype Liaison | |
| Steering Committee Representatives | |
| P&P primary | |
| P&P alternate | |
| Project |
PharmHU
|
Released
No
Back to top
